Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

Απλή σελίδα τεκμηρίου
dc.contributor.authorWong, E. T.en
dc.contributor.authorHess, K. R.en
dc.contributor.authorGleason, M. J.en
dc.contributor.authorJaeckle, K. A.en
dc.contributor.authorKyritsis, A. P.en
dc.contributor.authorPrados, M. D.en
dc.contributor.authorLevin, V. A.en
dc.contributor.authorYung, W. K.en
dc.date.accessioned2015-11-24T19:00:31Z
dc.date.available2015-11-24T19:00:31Z
dc.identifier.issn0732-183X-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19546
dc.rightsDefault Licence-
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectAstrocytoma/classification/*drug therapy/*pathologyen
dc.subjectBrain Neoplasms/classification/*drug therapy/pathologyen
dc.subjectGlioblastoma/classification/*drug therapy/*pathologyen
dc.subjectHumansen
dc.subjectKarnofsky Performance Statusen
dc.subjectLogistic Modelsen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Recurrence, Localen
dc.subjectProbabilityen
dc.subjectPrognosisen
dc.subjectProportional Hazards Modelsen
dc.subjectSalvage Therapyen
dc.subjectTreatment Outcomeen
dc.titleOutcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trialsen
heal.abstractPURPOSE: To determine aggregate outcomes and prognostic covariates in patients with recurrent glioma enrolled onto phase II chemotherapy trials. PATIENTS AND METHODS: Patients from eight consecutive phase II trials included 225 with recurrent glioblastoma multiforme (GBM) and 150 with recurrent anaplastic astrocytoma (AA). Their median age was 45 years (range, 15 to 82 years) and their median Karnofsky performance score was 80 (range, 60 to 100). Prognostic covariates were analyzed with respect to tumor response, progression-free survival (PFS), and overall survival (OS) by multivariate logistic and Cox proportional hazards regression analyses. RESULTS: Overall, 34 (9%) had complete or partial response, whereas 80 (21%) were alive and progression-free at 6 months (APF6). The median PFS was 10 weeks and median OS was 30 weeks. Histology was a robust prognostic factor across all outcomes. GBM patients had significantly poorer outcomes than AA patients. The APF6 proportion was 15% for GBM and 31% for AA, whereas the median PFS was 9 weeks for GBM and 13 weeks for AA. Results were also significantly poorer for patients with more than two prior surgeries or chemotherapy regimens. CONCLUSION: Histology is a dominant factor in determining outcome in patients with recurrent glioma enrolled onto phase II trials. Future trials should be designed with separate histology strata.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10561324-
heal.journalNameJ Clin Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1999-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ